Anna D. Garrett, PharmD, BCPS
Anna D. Garrett is a clinical pharmacist and president of Dr. Anna Garrett ( Her mission is to help women in midlife maximize their mojo! Contact her at [email protected]
Aspirin fails in Japanese primary prevention study
If patients have multiple risk factors, daily low-dose aspirin may not make much difference to their potential for CV events.
NSAIDs increase bleeding risk in patients taking anticoagulants
A Danish study of 150,900 patients found that the risk of serious bleeding doubled when patients were treated with NSAIDs.
Pre-op sepsis increases risk of thrombosis
A 2.3-million-patient study found that preoperative sepsis is a noteworthy risk factor for both arterial and venous thrombosis.
VTE treatment regimens have similar outcomes
Historically, unfractionated heparin (UFH) with a vitamin K antagonist has been the standard treatment for deep venous thrombosis (DVT) or pulmonary embolism. More recently, low-molecular-weight heparin (LMWH) combined with vitamin K antagonists has become the most common choice, but newer target-specific oral anticoagulants have widened the range of treatment options.
Poorly managed anticoagulation may contribute to risk of dementia
Excellent anticoagulation management appears to lower the risk of dementia over the long term in AF patients.
Aspirin effective for VTE prevention in orthopedic surgery
A recent review of eight trials found that aspirin was just as effective as heparin and warfarin in preventing blood clots after hip or knee replacements and caused 68% fewer serious bleeding events.
Can warfarin improve psychotic symptoms?
A study suggests that warfarin use may lead to a decrease in and even long-term remission of psychotic symptoms in patients with schizophrenia.
FDA comes out against aspirin for primary prevention
Available data indicated "serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain."
Warfarin safer than heparin for patients undergoing ablation
In a study of patients at high risk for stroke, patients without periprocedural warfarin who were bridged with low-molecular weight heparin showed a >10-fold increased odds of ischemic stroke or transient ischemic attack (TIA) in the 48 hours after ablation for atrial fibrillation, compared with those on uninterrupted warfarin.
Apixaban cuts stroke risk regardless of BP control
Apixaban cuts stroke risk regardless of BP control
A subanalysis of the Phase 3 ARISTOTLE trial indicates that apixaban reduces the risk of stroke regardless of whether a patient’s blood pressure is controlled.